公开(公告)号：US10323066B2

公开(公告)日：2019-06-18

申请号：US15510900

申请日：2015-09-17

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Caroline Ekblad ,  Elin Gunneriusson ,  Torbjörn Gräslund ,  Johan Seijsing ,  John Löfblom ,  Malin Lindborg ,  Fredrik Frejd ,  Lindvi Gudmundsdotter

IPC: C07K14/31 ,  C07K14/00 ,  C07K14/735 ,  C07K14/74 ,  A61K38/00

Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20190284241A1

公开(公告)日：2019-09-19

申请号：US16377722

申请日：2019-04-08

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Caroline Ekblad ,  Elin Gunneriusson ,  Torbjörn Gräslund ,  Johan Seijsing ,  John Löfblom ,  Malin Lindborg ,  Fredrik Frejd ,  Lindvi Gudmundsdotter

IPC: C07K14/00 ,  C07K14/735 ,  C07K14/74 ,  C07K14/31

Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20180118807A1

公开(公告)日：2018-05-03

申请号：US15842178

申请日：2017-12-14

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löfblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745 ,  C07K14/735 ,  C07K14/31 ,  C07K14/74 ,  C07K14/435 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US10562955B2

公开(公告)日：2020-02-18

申请号：US15842178

申请日：2017-12-14

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löfblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745 ,  C07K14/735 ,  C07K14/31 ,  C07K14/74 ,  C07K14/435 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2 X3 X4 AX6 X7 EIRWLPNL X16X17 X18 QRX21 AFIX25 X26LX28 X29. The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US09873729B2

公开(公告)日：2018-01-23

申请号：US14776319

申请日：2014-03-17

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745 ,  C07K14/735 ,  C07K14/74 ,  C07K14/31 ,  C07K14/435 ,  A61K38/00

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US09975943B2

公开(公告)日：2018-05-22

申请号：US14776319

申请日：2014-03-17

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745 ,  C07K14/735 ,  C07K14/74 ,  C07K14/31 ,  C07K14/435 ,  A61K38/00

CPC classification number: C07K14/745 ,  A61K38/00 ,  C07K14/31 ,  C07K14/435 ,  C07K14/70535 ,  C07K14/70539 ,  C07K2319/74

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20170260238A1

公开(公告)日：2017-09-14

申请号：US15510900

申请日：2015-09-17

Applicant: Affibody AB

Inventor： Lars Abrahmsén ,  Caroline Ekblad ,  Elin Gunneriusson ,  Torbjörn Gräslund ,  Johan Seijsing ,  John Löfblom ,  Malin Lindborg ,  Fredrik Frejd ,  Lindvi Gudmundsdotter

IPC: C07K14/00

CPC classification number: C07K14/00 ,  A61K38/00 ,  C07K14/31 ,  C07K14/70535 ,  C07K14/70539 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/74

Abstract: The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein said first and second monomer unit search comprises an FcRn binding motif. Said FcRn binding dimer binds FcRn with higher capacity compared to said first monomer unit or second monomer unit alone. The present disclosure also relates to the use of said FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

公开(公告)号：US20160031967A1

公开(公告)日：2016-02-04

申请号：US14776319

申请日：2014-03-17

Applicant: AFFIBODY AB

Inventor： Caroline Ekblad ,  Elin Gunneriusson ,  Malin Lindborg ,  Lars Abrahmsen ,  John Löfblom ,  Torbjörn Gräslund ,  Johan Seijsing

IPC: C07K14/745

CPC classification number: C07K14/745 ,  A61K38/00 ,  C07K14/31 ,  C07K14/435 ,  C07K14/70535 ,  C07K14/70539 ,  C07K2319/74

Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for the neonatal Fc receptor (in the following referred to as FcRn), and provides an FcRn binding polypeptide comprising the sequence EX2X3X4AX6X7 EIRWLPNL X16X17X18QRX21 AFIX25X26LX28X29 (SEQ ID NO: 1075). The present disclosure also relates to the use of such an FcRn binding polypeptide as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Abstract translation: 本公开涉及对新生儿Fc受体具有结合亲和力的一类工程化多肽（在下文中称为FcRn），并提供包含序列EX2X3X4AX6X7EIRWLPNL X16X17X18QRX21AFIX25X26LX28X29（SEQ ID NO：1075）的FcRn结合多肽。 本公开还涉及这种FcRn结合多肽作为用于改变药代动力学和药效学性质的试剂以及作为治疗剂的用途。